Textextraktion: pypdf | Seiten: 5
Decision of the Court of Appeal of the Unified Patent Court issued on 24 March 2026 Withdrawal pursuant to R. 265 RoP and Application for reimbursement of Court fees (R. 370 RoP) APPELLANTS (AND CLAIMANTS IN THE MAIN PROCEEDINGS BEFORE THE COURT OF FIRST INSTANCE) Sanofi Biotechnology SAS, Gentily, France (hereinafter referred to as “Sanofi”) and Regeneron Pharmaceuticals Inc., Tarrytown, United States of America (hereinafter referred to as “Regeneron”) both represented by Niels Hölder, attorney at law, and other attorneys at law of the law firm Carpmaels & Ransford LLP, London, UK RESPONDENTS (AND DEFENDANTS IN THE MAIN PROCEEDINGS BEFORE THE COURT OF FIRST INSTANCE) 1. Amgen N.V., Diegem, Belgium 2. Amgen S.R.L, Milan, Italy 3. Amgen GmbH, Munich, Germany 4. Amgen B.V., Breda, The Nether ...